Front. Pharmacol.Frontiers in PharmacologyFront. Pharmacol.1663-9812Frontiers Media S.A.120735610.3389/fphar.2023.1207356PharmacologyCorrectionCorrigendum: Elexacaftor-Tezacaftor-Ivacaftor treatment reduces abdominal symptoms in cystic fibrosis-early results obtained with the CF-specific CFAbd-ScoreMainz et al.10.3389/fphar.2023.1207356MainzJochen G.12*†ZagoyaCarlos1†PolteLouise1NaehrlichLutz34SasseLenny3EickmeierOlaf5SmacznyChristina5BaruchaAnton1BechingerLilith1DucksteinFranziska1KurzidimLudwik16EschenhagenPatience6CaleyLaura7PeckhamDaniel78‡SchwarzCarsten6‡1Cystic Fibrosis Center, Brandenburg Medical School (MHB) University, Klinikum Westbrandenburg, Brandenburg an der Havel, Germany2Faculty of Health Sciences Joint Faculty of the Brandenburg University of Technology Cottbus-Senftenberg, The Brandenburg Medical School Theodor Fontane and the University of Potsdam, Potsdam, Germany3Department of Pediatrics, Justus-Liebig-University Giessen, Giessen, Germany4Universities of Giessen and Marburg Lung Center (UGMLC), German Center for Lung Research (DZL), Giessen, Germany5Christiane Herzog CF-Zentrum Frankfurt am Main, Universitätsklinikum Frankfurt am Main CF-Zentrum, Frankfurt am Main, Germany6CF-Zentrum Westbrandenburg, Campus Potsdam, Klinikum Westbrandenburg, Potsdam, Germany7Leeds Institute of Medical Research at St James’s, University of Leeds, Leeds, United Kingdom8Adult Cystic Fibrosis Unit, St James’s University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Edited and reviewed by:Frederic Becq, University of Poitiers, France
*Correspondence: Jochen G. Mainz, j.mainz@klinikum-brandenburg.de
These authors have contributed equally to this work
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
A Corrigendum on Elexacaftor-Tezacaftor-Ivacaftor treatment reduces abdominal symptoms in cystic fibrosis-early results obtained with the CF-specific CFAbd-Score by Mainz JG, Zagoya C, Polte L, Naehrlich L, Sasse L, Eickmeier O, Smaczny C, Barucha A, Bechinger L, Duckstein F, Kurzidim L, Eschenhagen P, Caley L, Peckham D and Schwarz C (2022). Front. Pharmacol. 13:877118. doi: 10.3389/fphar.2022.877118gastrointestinalpatient reported outcome measureCFTR modulatorselexacaftorsymptom scoresection-at-acceptanceRespiratory Pharmacology
In the published article, there was an error in Figure 1 as published. The figure itself including the proportion of changes is correct. However, the numbers representing percent changes in reduction of symptoms do not correspond to those mentioned in the text but rather to a preliminary calculation from a smaller cohort of patients. Noteworthy, the improvement in abdominal symptoms assessed with the CFAbd-Score during ETI is in fact markedly higher in the now corrected version. The corrected Figure 1 and its caption appear below.
CFAbd-Score changes for the whole cohort and its 5 domains after therapy initiation (Table 1). Percent changes are calculated from estimated marginal means (EMMs) at week 24 of ETI therapy.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.